Clearmind Medicine Gains IRB Approval to Advance CMND-100 Trial to Parts B and C
CMND•Clearmind Medicine secured Johns Hopkins IRB approval to advance its Phase I/II CMND-100 trial into Parts B and C after completing initial safety and pharmacokinetic assessments. The multicenter study will assess single and multiple dose tolerability of the non-hallucinogenic MEAI-based candidate in healthy volunteers and Alcohol Use Disorder subjects.
1. IRB Approval Advances CMND-100 Trial
The Johns Hopkins Medicine IRB approved progression of Clearmind’s CMND-100 Phase I/II clinical study to Parts B and C following completion of initial single and multiple dose safety and pharmacokinetic assessments. This authorization permits dosing in both healthy volunteers and Alcohol Use Disorder subjects under the multicenter protocol.
2. Trial Design and Objectives
Parts B and C will evaluate tolerability, safety, and pharmacokinetics of CMND-100 in expanded cohorts, including multiple dosing regimens. The study aims to characterize the non-hallucinogenic MEAI-based candidate’s profile in healthy and AUD populations to inform future therapeutic development.
3. Company Pipeline and Intellectual Property
Clearmind holds 19 patent families with 31 granted patents covering its neuroplastogen-derived therapeutics. The company is focused on non-hallucinogenic compounds for underserved conditions, with CMND-100 as its lead candidate targeting Alcohol Use Disorder.
